Pharmacoeconomics and Outcomes Research: A Burgeoning Arena for Decision Making and Health Policy

A special issue of Pharmacy (ISSN 2226-4787). This special issue belongs to the section "Pharmacy Practice and Practice-Based Research".

Deadline for manuscript submissions: closed (1 December 2023) | Viewed by 2334

Special Issue Editors


E-Mail Website
Guest Editor
School of Pharmacy & Pharmaceutical Sciences, University of California, Irvine, CA 92612, USA
Interests: health policy; underserved populations; health economics; outcomes research; medications; opioid use disorder; older adult care; real-world data; long-term care; pharmacy; pharmacist-directed care; affordability and access to care
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, CA, USA
Interests: pharmacoeconomics; program and implementation evaluations; applied econometrics, and evidence-synthesis using Bayesian methods; provider behavior; opioid epidemic

Special Issue Information

Dear Colleagues,

Colliding challenges of increasingly expensive treatments, aging populations, and decelerating growth in life expectancy now confront clinicians and decision makers. There is a pressing need for insights informed by pharmacoeconomics and outcomes research to gauge clinical approaches, system-level interventions, and population-level policy development. Guiding quality care that incorporates the conservation of increasingly fixed resources is necessary. For this Special Issue “Pharmacoeconomics and Outcomes Research: A Burgeoning Arena for Decision Making and Health Policy,” we invite you to contribute original research, systematic reviews, meta-analyses, short reports, economic analyses, case studies, and commentaries salient to Pharmacoeconomics and Outcomes Research. 

Prof. Dr. Jonathan H Watanabe
Dr. Mark Bounthavong
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmacy is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • pharmacoeconomics
  • outcomes research
  • health policy
  • clinical decision making

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

12 pages, 265 KiB  
Review
A Comparison of Currently Approved Small Interfering RNA (siRNA) Medications to Alternative Treatments by Costs, Indications, and Medicaid Coverage
by Inder Sehgal, Kevin Eells and Imani Hudson
Pharmacy 2024, 12(2), 58; https://doi.org/10.3390/pharmacy12020058 - 28 Mar 2024
Viewed by 1750
Abstract
Small interfering RNA (siRNA)-based medications offer the ability to target previously undruggable targets and have now received FDA approval in five instances for orphan or uncommon diseases. The current siRNA “-sirans” are directed towards hepatic molecular targets. Because they are not conventional drug [...] Read more.
Small interfering RNA (siRNA)-based medications offer the ability to target previously undruggable targets and have now received FDA approval in five instances for orphan or uncommon diseases. The current siRNA “-sirans” are directed towards hepatic molecular targets. Because they are not conventional drug formulae, their ultimate clinical success will require overcoming multiple barriers beyond their pharmacology. The minimal patient numbers leave fewer patients to bear the costs of R&D and manufacture; therefore, the cost of these drugs, questionable third-party reimbursement, and competition from other drug classes for the same low number of patients are impediments to patient access. The parenteral route of administration, as well as emerging safety restrictions, are also drawbacks to siRNA. With this review, we document currently approved siRNA drugs by condition, approval date, administration route and frequencies. We have estimated the available patient populations for siran therapies using the U.S. Medicaid and Medicare populations and sought to identify the frequency with which large Medicaid formularies list siRNA drugs. Current comparative costs between the siRNA drugs and alternatives have been presented, and the review summarizes current adverse events as reported to the FDA’s Adverse Event Reporting System. Our review and data indicate that sirans are extremely expensive and seldom recognized in posted Medicaid formularies. However, alternative treatments for these conditions are no less costly, usually do not have significantly different adverse events, and are often less convenient for the patient. Full article
Back to TopTop